Lingyang Hua1, Daijun Wang1, Hongda Zhu1, Jiaojiao Deng1, Shihai Luan1, Haixia Chen2, Shuchen Sun1, Hailiang Tang1, Qing Xie1, Hiroaki Wakimoto3, Ye Gong4,5. 1. Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Middle Wulumuqi Road, Jingan District, Shanghai, 200040, China. 2. Department of Neuropathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 3. Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. hwakimoto@mgh.harvard.edu. 4. Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Middle Wulumuqi Road, Jingan District, Shanghai, 200040, China. drgongye@163.com. 5. Department of Critical Care Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. drgongye@163.com.
Abstract
PURPOSE: The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients' outcomes and best treatment strategies based on tumor features. METHODS: To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. RESULTS: A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). CONCLUSIONS: This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.
PURPOSE: The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients' outcomes and best treatment strategies based on tumor features. METHODS: To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. RESULTS: A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PMpatients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). CONCLUSIONS: This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.
Authors: Douglas Kondziolka; Agam D Patel; Hideyuki Kano; John C Flickinger; L Dade Lunsford Journal: Am J Clin Oncol Date: 2016-10 Impact factor: 2.339
Authors: Arkadiusz Nowak; Tomasz Dziedzic; Tomasz Czernicki; Przemysław Kunert; Andrzej Marchel Journal: Neurol Neurochir Pol Date: 2014-05-24 Impact factor: 1.621
Authors: Ayal A Aizer; Nils D Arvold; Paul Catalano; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ossama Al-Mefty; Patrick Y Wen; David A Reardon; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Stephanie E Weiss; Shakti H Ramkissoon; Malak Abedalthagafi; Sandro Santagata; Ian F Dunn; Brian M Alexander Journal: Neuro Oncol Date: 2014-06-02 Impact factor: 12.300
Authors: Alessandro Ricci; Hambra Di Vitantonio; Danilo De Paulis; Mattia Del Maestro; Massimo Gallieni; Soheila Raysi Dechcordi; Sara Marzi; Renato Juan Galzio Journal: Surg Neurol Int Date: 2017-01-19
Authors: Hongda Zhu; Wenya Linda Bi; Ayal Aizer; Lingyang Hua; Mi Tian; Jiaojiao Den; Hailiang Tang; Hong Chen; Yin Wang; Ying Mao; Ian F Dunn; Qing Xie; Ye Gong Journal: Cancer Med Date: 2019-01 Impact factor: 4.452
Authors: Hanne-Rinck Jeltema; Marnix R Jansen; Adriaan R E Potgieser; Antoinette D I van Asselt; Mart A A M Heesters; Anouk van de Hoorn; Andor W J M Glaudemans; J Marc C van Dijk Journal: Neuroradiology Date: 2021-03-10 Impact factor: 2.804